These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11349626)

  • 21. [ASSENT III and GUSTO V: is it the end of combination therapy with GPIIb/IIIa blockers and thrombolytics in myocardial infarction?].
    Vahanian A
    Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):6-7. PubMed ID: 12471654
    [No Abstract]   [Full Text] [Related]  

  • 22. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
    Gold HK; Garabedian HD; Dinsmore RE; Guerrero LJ; Cigarroa JE; Palacios IF; Leinbach RC
    Circulation; 1997 Apr; 95(7):1755-9. PubMed ID: 9107158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of abciximab in the treatment of coronary artery disease.
    Gabriel HM; Oliveira EI
    Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction.
    Gibson CM; Anshelevich M; Murphy S; Luu L; Hynes C; Kliris J; Kermgard S; Otten MH; Antman EM; Cannon CP; Braunwald E;
    Am J Cardiol; 2000 Dec; 86(12):1378-9, A5. PubMed ID: 11113418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
    Rebeiz AG; Johanson P; Green CL; Crater SW; Roe MT; Langer A; Giugliano RP; Lincoff AM; Newby LK; Harrington RA; Topol EJ; Califf RM; Wagner GS; Krucoff MW
    Am J Cardiol; 2005 Mar; 95(5):611-4. PubMed ID: 15721101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction.
    Bates ER
    Curr Opin Cardiol; 1998 Jul; 13(4):274-9. PubMed ID: 10091023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Confusion in reperfusion.
    Gibson CM
    J Am Coll Cardiol; 2003 Oct; 42(7):1186-7. PubMed ID: 14522477
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of acute coronary syndromes.
    Schulman SP; Fessler HE
    Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
    [No Abstract]   [Full Text] [Related]  

  • 37. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition.
    Bush HS
    J Emerg Med; 2003 Nov; 25(4):421-6. PubMed ID: 14654184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Too much, too little, or none at all: dealing with substandard and fake drugs.
    Wan Po AL
    Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
    [No Abstract]   [Full Text] [Related]  

  • 40. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
    J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.